I mentioned soon after the announcement that I didn’t think it was going to happen and I couldn’t explain why I had that feeling. Still can’t. But to throw out my best guess, I think it was a real opportunity but a few things then occurred which made it a pointless trial.

- Mexico looked quick and easy
- Remdesivir has continued to have bad press
- Trial numbers increased and a plan to unblind became a possibility
- I’m guessing that funding discussions have advanced to a point where approval is needed ASAP if agencies like BARDA are to pony up
- The more they see the bloodwork the more they are convinced (thus the confidence on the calls and the decision to unblind) that approval will be possible

Add it all up and why bother adding the workload for a trial that likely wouldn’t fill before all the other dominoes fall. I just think it was good strategy that became less optimal than the current strategy. Just a big fat guess.

What I am hoping for today is the dang announcement on distribution. If another company is timing their PR with ours maybe we still have a chance today at what would otherwise be an abnormal time for Cytodyn. (Not 6am est)